BACKGROUND: Dabigatran directly inhibits thrombin and is used in primary and secondary stroke prevention in individuals with nonvalvular atrial fibrillation. The prodrug dabigatran etexilate is absorbed by enteral P-glycoprotein (ABCB1) and then activated by hepatic and intestinal carboxylesterases (CES1) to produce active metabolites. Variations in dabigatran metabolism because of genetics may affect concentration levels and clinical outcomes. STUDY QUESTION: We conducted a study to assess how polymorphisms in the CES1 (rs2244613) and ABCB1 (rs4148738) genes affect the through plasma level (c min ) of dabigatran and its correlation to clinical outcomes. STUDY DESIGN: Retrospective multicentric study of consecutive patients on dabigatran therapy. Examination of CES1 rs2244613 and ABCB1 rs4148738 polymorphisms, c min 12 hours after administration, clinical follow-up (ischemic stroke, major or clinically relevant hemorrhage, myocardial infarction, other thromboembolism, and death). MEASURES AND OUTCOMES: A total of 432 patients received treatment for an average of 19.78 months (SD of 20.165). The sex distribution of the patients was 56.5% male, and the average age was 67.56 years (SD of 14.7). The ABCB1 variant genotype was present in 67.8% of patients, whereas 37.5% carried the CES1 polymorphism. RESULTS: Compared with wild-type patients, patients with the CES1 variant had significantly lower dabigatran plasma levels (with a mean difference of 16.986; 95% confidence interval, 5.794-28.178 ng/mL, P = 0.003). We also found a significant risk of major bleeding in patients carrying the ABCB1 rs4148738 allele (hazard ratio = 1.99, confidence interval 95% 1.10 to 3.59, P = 0.024). CONCLUSIONS: The CES1 variant genotype rs2244613 is closely linked with reduced c min of dabigatran. Carriers of the ABCB1 rs4148738 polymorphism exhibit a tendency toward higher plasma levels of dabigatran, which leads to a significantly increased risk of bleeding.

Department of Neurology 2nd Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic

Department of Neurology Military University Hospital Prague Prague Czech Republic

Laboratory of Molecular Diagnostics Hospital Na Homolce Prague Czech Republic

Pharmakl spol s r o Prague Czech Republic; and

Zobrazit více v PubMed

WHO. The Top 10 Causes of Death; 2020.

Bogiatzi C, Hackam DG, McLeod AI, et al. Secular trends in ischemic stroke subtypes and stroke risk factors. Stroke. 2014;45:3208–3213.

Ferro JM, Coutinho JM, Dentali F, et al. Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis: a randomized clinical trial. JAMA Neurol. 2019;76:1457–1465.

EMA. Pradaxa—European Medicines Agency—European Union; 2008. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa#product-information-section . Accessed August 25, 2023.

Robinson AA, Trankle CR, Eubanks G, et al. Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi. JAMA Cardiol. 2020;5:685–692.

Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.

Testa S, Paoletti O, Legnani C, et al. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost. 2018;16:842–848.

Testa S, Legnani C, Antonucci E, et al. Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost. 2019;17:1064–1072.

Škorňová I, Samoš M, Bolek T, et al. Direct oral anticoagulants plasma levels in patients with atrial fibrillation at the time of bleeding: a pilot prospective study. J Cardiovasc Pharmacol. 2021;78:e122–e127.

Nosáľ V, Petrovičová A, Škorňová I, et al. Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study. Eur J Clin Pharmacol. 2022;78:557–564.

Laizure SC, Parker RB, Herring VL, et al. Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis. Drug Metab Dispos. 2014;42:201–206.

Pare G, Eriksson N, Lehr T, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013;127:1404–1412.

Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost. 2009;15(suppl 1):9S–16S.

Sychev DA, Levanov AN, Shelekhova TV, et al. The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty. Pharmgenomics Pers Med. 2018;11:127–137.

Dimatteo C, D'Andrea G, Vecchione G, et al. Pharmacogenetics of dabigatran etexilate interindividual variability. Thromb Res. 2016;144:1–5.

Lahteenmaki J, Vuorinen AL, Pajula J, et al. Pharmacogenetics of bleeding and thromboembolic events in direct oral anticoagulant users. Clin Pharmacol Ther. 2021;110:768–776.

Zhu Z, Qian C, Su C, et al. The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord. 2022;22:481.

Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J. 2017;38:860–868.

Kalita Z, Keller O, Bar M, et al. Doporučený Postup Sekundární Prevence Recidivy Po Akutní Cévní Mozkové Příhodě; 2021. Available from: https://www.cmp.cz/guidelines-a-postupy . Accessed July 10, 2023.

Gong IY, Kim RB. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol. 2013;29:S24–S33.

Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63:321–328.

Ruzsiková A, Tomek A, Zvarová M, et al. Monitorování Účinku Nových Orálních Antikoagulancií. Neurologie Pro Praxi. 2014;15:3.

Kaatz S, Ahmad D, Spyropoulos AC, et al. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13:2119–2126.

Olšerová A, Janský P, Šrámková T, et al. Dabigatran pharmacogenetics and secondary prevention of ischemic stroke. Česká Slov Neurol Neurochir. 2015;2014:567026.

Kanuri SH, Kreutz RP. Pharmacogenomics of novel direct oral anticoagulants: newly identified genes and genetic variants. J Pers Med. 2019;9:7.

PharmGKB. SNP rs4148738; 2022. Available at: https://www.ncbi.nlm.nih.gov/snp/rs4148738 . Accessed June 13, 2023.

PharmGKB. SNP rs2244613; 2022. Available at: https://www.ncbi.nlm.nih.gov/snp/rs2244613 . Accessed June 25, 2023.

Chin PK, Wright DFB, Zhang M, et al. Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C. Drugs R D. 2014;14:113–123.

Liu Y, Yang C, Qi W, et al. The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics in healthy Chinese subjects. Pharmgenomics Pers Med. 2021;14:477–485.

Raymond J, Imbert L, Cousin T, et al. Pharmacogenetics of direct oral anticoagulants: a systematic review. J Pers Med. 2021;11:37.